Business Context and Reporting Period
Company: Solesence, Inc. (formerly Nanophase Technologies Corporation)
Reporting Period: Fiscal year ended December 31, 2024
Overview: Solesence is a science-driven company focused on skin health and beauty markets. It operates as a single business segment with three primary product lines: Consumer Products (finished cosmetics/sunscreen), Personal Care Ingredients (APIs like zinc oxide), and Advanced Materials. The company rebranded from Nanophase Technologies Corporation in March 2025. Operations are centered in three leased facilities in the Chicago, Illinois area.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $52.35 million | $37.30 million |
| Gross Profit | $16.19 million | $7.83 million |
| Gross Margin | 30.9% | 21.0% |
| Net Income (Loss) | $4.24 million | ($4.39 million) |
| Operating Cash Flow | $1.97 million | ($2.01 million) |
| Cash and Equivalents (Year End) | $1.41 million | $1.72 million |
| Total Debt (Related Party) | $5.00 million | $10.81 million |
| Inventory (Net) | $20.27 million | $10.03 million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 40% year-over-year, driven primarily by the Consumer Products segment, which grew from $25.2 million (68% of total) in 2023 to $44.4 million (85% of total) in 2024.
- Profitability Turnaround: The company returned to profitability, reporting a net income of $4.24 million in 2024 compared to a net loss of $4.39 million in 2023. This was aided by a significant increase in gross margin and a reduction in SG&A expenses.
- Inventory Build: Net inventory more than doubled to $20.27 million, necessitating a $1.99 million reserve for excess and obsolete items, up from $0.68 million in 2023.
- Debt Reduction: Total related-party debt outstanding decreased by approximately $5.8 million due to repayments and the conversion of $6.0 million in Series X Preferred Stock to common equity.
Guidance, Outlook, and Risks
- Strategic Focus: Management intends to prioritize the Consumer Products line as the primary growth engine, leveraging proprietary "Active Stress Defense" technologies. Advanced Materials are no longer a strategic focus.
- Capital Expenditures: The company expects capital spending for 2025 to range between $6 million and $8 million to support facility expansion and equipment upgrades.
- Debt Maturity: Related-party debt facilities (A/R Revolver, Inventory Facility, and Term Loan) mature on October 1, 2025. The lender has committed to refinancing with a maturity date after April 1, 2026.
- Customer Concentration: The top three customers accounted for 52% of total revenue in 2024. The largest customer (Consumer Products) represented 32% of revenue.
- Legal Resolution: A long-standing dispute with BASF Corporation regarding exclusivity provisions was settled in April 2024, resulting in a mutual release of claims and an amended supply agreement.
- Risks: Key risks include dependence on a limited number of customers, supply chain constraints for high-purity zinc, and the ability to pass through inflationary cost increases to customers.
Investor Verification Checklist
- Inventory Valuation: Verify the adequacy of the $1.99 million inventory reserve given the doubling of inventory levels and the specific identification of obsolete materials.
- Debt Refinancing: Confirm the execution of the refinancing commitment for the $5 million related-party debt maturing in October 2025.
- Customer Concentration: Monitor the stability of the top three customers, particularly the 32% revenue contributor, as their loss would materially impact operations.
- Capital Expenditure Execution: Track the $6–8 million planned CapEx for 2025 to ensure it aligns with projected revenue growth and does not strain liquidity.
- Related Party Transactions: Review the terms of the debt and equity transactions with affiliates of the controlling shareholder (Bradford T. Whitmore), who owns approximately 71% of the company.